AC Immune Ltd (ACIU) Stock Forecast & Price Target
AC Immune Ltd · NASDAQ
$2.31+0.08 (+3.59%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering AC Immune Ltd, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $8.00 to $8.00, so the covering firms are broadly aligned. The average target of $8.00 sits 246% above the current $2.31. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees revenue growth near 324% this year and 696% next, consensus EPS building from about $-0.18 next quarter toward $0.49 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to AC Immune Ltd.
As of Jul, 1 of 1 firms rate ACIU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACIU EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.20 – $-0.15 · 3 analysts · +10% YoY
Next period, 3 analysts expect AC Immune Ltd to earn $-0.18 a share (range $-0.20 – $-0.15), versus $-0.16 a year earlier. Full-year consensus is $-0.48, growing to $0.49 the year after.
REVENUE · NEXT QUARTER
$202.0K
Range $0 – $808.0K · 3 analysts · -78% YoY
Revenue is expected to reach $202.0K (range $0 – $808.0K), -78.5% year-over-year. Full-year consensus is $36.3M, rising to $87.8M next year.
Top analysts covering AC Immune Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACIU.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$12.00+419.5% to target
Overall win rate
46%
+ Follow
#2
Thomas Shrader
BTIG
Buy
$8.00+246.3% to target
Coverage
—
+ Follow
#3
Marc Goodman
Leerink Partners
Buy
No targeton ACIU
Coverage
—
+ Follow
ACIU stock forecast FAQ
What is ACIU's average 12-month price target?+
The 1 analysts with a live target average $8.00 for AC Immune Ltd over the next 12 months, ranging from a $8.00 high to a $8.00 low.
Is ACIU stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover ACIU?+
1 analysts have an active rating on AC Immune Ltd, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACIU?+
Among analysts who currently cover ACIU, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $12.00 target.
What is AC Immune Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.20 – $-0.15) across 3 analysts. Full-year EPS is projected at $-0.48, rising to $0.49 the following year.
How much revenue is AC Immune Ltd expected to report next quarter?+
Consensus revenue is $202.0K (range $0 – $808.0K). Full-year revenue is projected at $36.3M, growing to $87.8M next year.
Have analysts been upgrading or downgrading ACIU lately?+
As of Jul, 1 of 1 firms rate ACIU a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACIU calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
